To include your compound in the COVID-19 Resource Center, submit it here.

Keryx sags after withdrawing guidance

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) fell $1.08 (17%) to $5.15 Tuesday after it reported 3Q17

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE